SHUKRA PHARMACEUTICALS L Latest Share Price (SHUKRAPHAR)
TODAY IN ONE LINE
SHUKRAPHAR slipped 0.7%, in line with Nifty's 0.0% move.
it trades at a P/E of 63.03. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
SHUKRA PHARMACEUTICALS L flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Promoter HoldingPromoters hold 51.0% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest SHUKRA PHARMACEUTICALS L News
What changed recently?
Recent events, corporate actions, and announcements.
SHUKRA PHARMACEUTICALS L valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for SHUKRA PHARMACEUTICALS L, framed against the sector median so the premium or discount is obvious at a glance.
SHUKRA PHARMACEUTICALS L trades at a P/E of 63.03× and P/B of 21.83×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
SHUKRA PHARMACEUTICALS L technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for SHUKRA PHARMACEUTICALS L — derived from the latest tape, not yesterday's close.
SHUKRA PHARMACEUTICALS L last traded at ₹54.2 with an intraday range of ₹54.2–₹55.79 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹54.20| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 58.44 | +4.24 | +7.82% |
| R3 | 56.85 | +2.65 | +4.89% |
| R2 | 56.32 | +2.12 | +3.91% |
| R1 | 55.26 | +1.06 | +1.96% |
| PIVOT | 54.73 | 0.53 | 0.98% |
| CURRENT | 54.20 | — | — |
| S1 | 53.67 | -0.53 | -0.98% |
| S2 | 53.14 | -1.06 | -1.96% |
| S3 | 52.08 | -2.12 | -3.91% |
| S4 | 50.49 | -3.71 | -6.85% |
SHUKRAPHAR is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹54.46–₹54.89
Trading Inside opening range
SHUKRA PHARMACEUTICALS L financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for SHUKRA PHARMACEUTICALS L — consolidated or standalone — with margins, YoY growth and key ratios inline.
SHUKRA PHARMACEUTICALS L reports its full P&L, balance sheet, cash flow and ratios on this page — current reported EPS of ₹0.34.
| Metric | — | Mar 2026 |
|---|---|---|
| Revenue from Operations | — | 57 |
| Other Income | — | 5 |
| Total Income | — | 61 |
| — | 16 | |
| Gross ProfitDerived | — | 41 |
| Gross Margin %Derived | — | 72.06% |
| — | 12 | |
| EBITDA (Operating Profit)Derived | — | 29 |
| OPM %Derived | — | 50.66% |
| — | 5 | |
| Profit Before Tax (PBT) | — | 29 |
| — | 7 | |
| Effective Tax %Derived | — | 23.37% |
| Total Profit for Period | — | 22 |
| Net Profit (Owner's PAT)Derived | — | 22 |
| Net Profit Margin %Derived | — | 38.89% |
| Earnings Per Share (EPS ₹) | — | 0.50 |
| Diluted Shares Outstanding (Cr) | — | 44 |
| Other Comprehensive Income (Net of Tax) | — | -0 |
| Total Expenses (incl. D&A & Interest) | — | 33 |
| Material Cost % of RevenueDerived | — | 34.29% |
| Employee Cost % of RevenueDerived | — | 12.41% |
| Other Cost % of RevenueDerived | — | 9.00% |
| Interest Coverage (x)Derived | — | 23.14x |
| Period | Mar 2026 | Trend |
|---|---|---|
| Revenue from Operations | 57 | |
| Other Income | 5 | |
| Total Income | 61 | |
16 | ||
| Gross ProfitDerived | 41 | |
| Gross Margin %Derived | 72.06% | |
12 | ||
| EBITDA (Operating Profit)Derived | 29 | |
| OPM %Derived | 50.66% | |
5 | ||
| Profit Before Tax (PBT) | 29 | |
7 | ||
| Effective Tax %Derived | 23.37% | |
| Total Profit for Period | 22 | |
| Net Profit (Owner's PAT)Derived | 22 | |
| Net Profit Margin %Derived | 38.89% | |
| Earnings Per Share (EPS ₹) | 0.50 | |
| Diluted Shares Outstanding (Cr) | 44 | |
| Other Comprehensive Income (Net of Tax) | -0 | |
| Total Expenses (incl. D&A & Interest) | 33 | |
| Material Cost % of RevenueDerived | 34.29% | |
| Employee Cost % of RevenueDerived | 12.41% | |
| Other Cost % of RevenueDerived | 9.00% | |
| Interest Coverage (x)Derived | 23.14x |
SHUKRA PHARMACEUTICALS L segment analysis : revenue and profit mix.
Disclosed business segments at SHUKRA PHARMACEUTICALS L with their share of revenue and profit, switchable between consolidated and standalone reporting.
SHUKRA PHARMACEUTICALS L discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for SHUKRA PHARMACEUTICALS L.
Our AI distills the core fundamental drivers supporting SHUKRA PHARMACEUTICALS L, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 82 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Income thesis breaks if the dividend is cut or yield falls below 0.01%.
SHUKRA PHARMACEUTICALS L peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SHUKRA PHARMACEUTICALS L is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
SHUKRA PHARMACEUTICALS L chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for SHUKRA PHARMACEUTICALS L — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
SHUKRA PHARMACEUTICALS L delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for SHUKRA PHARMACEUTICALS L over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in SHUKRA PHARMACEUTICALS L stood at 32.4% of traded volume, against a 20-day average of 50.1%.
SHUKRA PHARMACEUTICALS L announcements: results, concalls, ratings, M&A.
Filings SHUKRA PHARMACEUTICALS L sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
SHUKRA PHARMACEUTICALS L files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 12 documents below.
Shareholders meeting
Shukra Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 28, 2026
General Updates
Shukra Pharmaceuticals Limited has informed the Exchange about General Updates
General Updates
Shukra Pharmaceuticals Limited has informed the Exchange about General Updates
Outcome of Board Meeting
Shukra Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 02, 2026.
Copy of Newspaper Publication
Shukra Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
SHUKRA PHARMACEUTICALS L dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue SHUKRA PHARMACEUTICALS L has declared, sequenced by announce and record date.
SHUKRA PHARMACEUTICALS L corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About SHUKRA PHARMACEUTICALS L: business, sector, key facts.
What SHUKRA PHARMACEUTICALS L does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
SHUKRA PHARMACEUTICALS L is a listed Indian equity.
SHUKRA PHARMACEUTICALS L
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B BLACKBIO DX (3BBLACKBIO) Share PricePeer
- ABBOTT INDIA (ABBOTINDIA) Share PricePeer
- ACUTAAS CHEMICALS (ACUTAAS) Share PricePeer
- ANLON HEALTHCARE (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about SHUKRA PHARMACEUTICALS L (SHUKRAPHAR).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of SHUKRA PHARMACEUTICALS L (SHUKRAPHAR)?
The current share price of SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) is ₹54.20. Today, the stock has declined by ₹0.40 (0.73%), trading in a range of ₹54.20 to ₹55.79. The stock opened at ₹54.58 with a trading volume of 5,96,528 shares.
02Is SHUKRA PHARMACEUTICALS L stock a good investment for long-term?
SHUKRA PHARMACEUTICALS L can be considered for long-term investment based on several factors. The company has a market capitalization of ₹0, P/E ratio of 63.03, ROE of 0%, and ROCE of 0%. The dividend yield stands at 0.02%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of SHUKRA PHARMACEUTICALS L stock?
The 52-week high price of SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) is ₹58.20, while the 52-week low is ₹40.06. Currently trading at ₹54.20, the stock is 35.3% above its 52-week low and 6.87% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy SHUKRA PHARMACEUTICALS L stock at the current price?
Whether to buy SHUKRA PHARMACEUTICALS L stock at ₹54.20 depends on multiple factors. The stock is currently trading with a P/E ratio of 63.03 and P/B ratio of 21.83. Today's performance shows a loss of 0.73%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of SHUKRA PHARMACEUTICALS L and when is the next dividend?
SHUKRA PHARMACEUTICALS L offers a dividend yield of 0.02%, which means for every ₹100 invested at the current price of ₹54.20, you can expect to receive approximately ₹0.02 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06How is SHUKRA PHARMACEUTICALS L stock performing today in the market?
SHUKRA PHARMACEUTICALS L stock opened at ₹54.58 and is currently trading at ₹54.20, showing a decline of ₹0.40 (0.73%). The intraday high is ₹55.79 and low is ₹54.20. The trading volume stands at 5,96,528 shares, indicating moderate market participation today.
07What is the P/E ratio of SHUKRA PHARMACEUTICALS L and what does it indicate?
SHUKRA PHARMACEUTICALS L has a Price-to-Earnings (P/E) ratio of 63.03, which means investors are willing to pay 63.03 for every ₹1 of earnings. With an EPS of ₹0.34, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
08What is the market capitalization of SHUKRA PHARMACEUTICALS L?
SHUKRA PHARMACEUTICALS L has a market capitalization of ₹0, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹54.20) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
The data, ratios and commentary about SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.